80 likes | 240 Vues
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products. Products > T98G Transfection Reagent (Glioblastoma Cells, CRL-1690).
E N D
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products >T98G Transfection Reagent (Glioblastoma Cells, CRL-1690) Altogen Biosystems offers the T98G Transfection Reagent among a host of 100+ cell line specific In Vitro Transfection Kits. T98G Transfection Reagent is a nanoparticle-based liposome formulation, and it has been developed to provide high transfection efficiency with T98G cells. This cell line is a good host for biomedical and brain cancer. When cultured in vitro, T98G cells are a monolayer and adhere to the surface of the culture flask. Other applications include drug discovery, gene expression studies, molecular and cell biology research applications. Purchase T98G Transfection Kit at www.Altogen.com Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989-0841 email techserv@altogen.com
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products >T98G Transfection Reagent (Glioblastoma Cells, CRL-1690) T98G Cell Line Description and Applications The T98 cell line originates from the brain tissue of a 61-year old Caucasian male suffering from GBM or glioblastoma multiforme. GBM is the most common and aggressive malignant brain tumor. The T98 cell line is not tumorigenic, displays fibroblast morphology and has polyploidy with a hyperpentaploid chromosome count. The cell line has a modal chromosome number range of 128 to 132. The T98 cell line is anchorage-independent, and when the cells are deprived or crowded, they enter a viable G1 arrested state. The T98 cell line has research applications for brain tumor therapeutics as well as a wide array of biomedical research. High Density T98G Cell Lineatcc.org Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989-0841 email techserv@altogen.com
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products >T98G Transfection Reagent (Glioblastoma Cells, CRL-1690) T98G Transfection Protocol 1. Plate 10,000 - 15,000 T98G cells per well in 0.5 ml of complete growth medium 12–24 hours prior to transfection 2. Wash with 1xPBS and add 0.5 ml of fresh growth medium 3. Prepare transfection complexes by mixing 40 µl of serum-free medium, 5.5 µl of transfection reagent, and • 750 ng DNA (or mRNA), or • 30 nM - 50 nM of siRNA (or microRNA) *Referred to a final volume including growth medium 4. Incubate transfection complexes at RT for 15 - 30 minutes 5. Optional: Add 2 µl of Complex Condenser. This reagent reduces the size of transfection complex, therefore increasing transfection efficiency; however, it may increase cell toxicity 6. Add prepared transfection complexes to 0.5 ml of complete growth medium with T98G cells (from step 2) 7. Incubate cells at 37ºC in a humidified CO2 incubator 8. Assay for phenotype or target gene expression 48 - 72 hours after transfection Optional: Transfection efficiency can be increased by addition of Transfection Enhancer reagent. Add 2 µl of Transfection Enhancer reagent 12-24 hours after transfection If the viability of T98G cells being transfected is affected at 16 - 24 hours post-transfection, the level of cytotoxicity can be decreased by changing the growth medium and eliminating redundant exposure of cells to transfectant Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989-0841 email techserv@altogen.com
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products >T98G Transfection Reagent (Glioblastoma Cells, CRL-1690) General Lipoplex-mediated Transfection Mechanism of Action Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989-0841 email techserv@altogen.com
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products >T98G Transfection Reagent (Glioblastoma Cells, CRL-1690) T98G Transfection Kit Product Details • A nanoparticle-based liposome formulation • Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA • Kit includes Transfection Enhancer reagent and recommended transfection protocol • High transfection efficacy in the presence of serum • Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid • Reproducible transfection results • Works well for standard reverse transfection and high-throughput applications • Developed and manufactured by Altogen Biosystems (www.Altogen.com) Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989-0841 email techserv@altogen.com
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products >T98G Transfection Reagent (Glioblastoma Cells, CRL-1690) Data Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in the T98G cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=6).
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products >T98G Transfection Reagent (Glioblastoma Cells, CRL-1690) Data Figure 2. Protein expression of Cyclophilin B in T98G cells. DNA plasmid expressing Cyclophilin B or siRNA targeting Cyclophilin B were transfected into T98G cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products >T98G Transfection Reagent (Glioblastoma Cells, CRL-1690) T98G Transfection Kit Benefits • Pre-optimized transfection protocol for T98G cell line • Compatible with DNA, small RNA (siRNA, shRNA, miRNA), mRNA, and small protein complexing • Free of serum and protein of animal origin • Compatible with standard and reverse transfection methods (both protocols provided in the kit manual) • Easy to use T98G transfection protocol ensures great performance with expedited experimental timeline • Equally efficient for single or multiple transfections • Can be used for transient transfection and development of stable T98G cell lines • Bio-degradable after endocytosis • Used for preclinical research worldwide Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989-0841 email techserv@altogen.com